No Data
No Data
Buy Rating Affirmed for Verastem Amid Positive Developments and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX)
Express News | HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $17.5 Price Target
Verastem Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 47.68% HC Wainwright & Co. → $17.5 Reiterates Buy → Buy 03/19/2024 47.68% HC Wainwright & Co. →
Buy Rating on Verastem: Promising Pipeline and Regulatory Milestones Drive Positive Outlook
RBC Capital Sticks to Their Buy Rating for Verastem (VSTM)
baglady : way to go!